Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Tutkia BAR502:n turvallisuutta, siedettävyyttä, farmakokinetiikkaa ja farmakodynamiikkaa terveillä henkilöillä

keskiviikko 16. syyskuuta 2026 päivittänyt: BAR Pharmaceuticals s.r.l.

Vaihe I, kaksiosainen tutkimus, jossa tutkitaan BAR502:n yksittäisten ja useiden nousevien annosten turvallisuutta, siedettävyyttä, farmakokinetiikkaa ja farmakodynamiikkaa terveillä henkilöillä

First-in-human, single centre, two parts, dose-escalation, parallel-group, safety, tolerability, pharmacokinetic and pharmacodynamic Phase I study. Part A: randomised, double-blind, placebo-controlled, single ascending dose study.

Part B: open label, multiple ascending dose study.

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

First-in-human, single centre, two parts, dose-escalation, parallel-group, safety, tolerability, pharmacokinetic and pharmacodynamic Phase I study. Part A: randomised, double-blind, placebo-controlled, single ascending dose study to evaluate the safety and tolerability of BAR502 and matching placebo across 4 single ascending doses administered to 4 cohorts of 8 healthy subjects each.

Part B: open label, multiple ascending dose study to evaluate the safety and tolerability of two ascending doses of BAR502, considered as safe in study Part A, when administered as multiple doses to 2 cohorts of 10 healthy subjects each.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

43

Vaihe

  • Vaihe 1

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

  • Sveitsi
      • Arzo, Sveitsi, CH-6864
        • CROSS Research S.A. Phase I Unit

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 55 vuotta (Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  1. Informed consent: signed written informed consent before inclusion in the study

  2. Sex and Age: men/women, 18-55 years old inclusive

  3. Body Mass Index: 18.5-30 kg/m2 inclusive

  4. Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-99 bpm, measured after 5 min at rest in the sitting position

  5. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire study

  6. Renal functionality: estimated glomerular filtration rate calculated using the Cockcroft-Gault equation and normalized to an average surface area of 1.73 m2 ≥ 90 mL/min at screening

  7. Tobacco: non-smokers, non-users of nicotine containing products and non-users of Vapo e-cigarettes for at least 3 months prior to study screening

  8. Contraception and fertility (women only): women of non-child-bearing potential or in post-menopausal status for at least 1 year, defined as such when there is either:

    1. 12 months of spontaneous amenorrhea or
    2. 6 weeks documented postsurgical bilateral oophorectomy with or without hysterectomy will be admitted. For all women, pregnancy test result must be negative at screening and on Day -1 of each study part.

  9. Contraception (men only): men will either be sterile or agree to use one of the following approved methods of contraception from the first investigational medicinal product administration until at least 90 days after the last administration, also in case their partner is currently pregnant:

    1. A male condom with spermicide
    2. A sterile sexual partner or a partner in post-menopausal status for at least 1 year
    3. Use by the female sexual partner of an IUD, a female condom with spermicide, a contraceptive sponge with spermicide, a diaphragm with spermicide, a cervical cap with spermicide, or hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit or: True abstinence

Exclusion Criteria:

  1. ECG 12-leads (supine position): clinically significant abnormalities, in particular QTcF > 450 ms
  2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study
  3. Laboratory analyses: clinically significant abnormal laboratory values at screening indicative of physical illness or any acute laboratory abnormality at Screening which, in the opinion of the Investigator, should preclude participation in the study of an investigational compound. INR > 1.2
  4. Diseases: significant history of renal, hepatic (in particular, liver or hepatobiliary diseases as indicated by serum alanine aminotransferase, aspartate aminotransferase or total bilirubin levels exceeding the upper limit of normality), gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study
  5. Gallbladder: history of cholecystectomy, presence of gallstones or clinically significant gallbladder abnormalities that may interfere with the aim of the study
  6. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
  7. Medications: medications, including over the counter medications, homeopathic preparations, vitamins, food supplements and herbal remedies for 3 weeks before the start of the study
  8. Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study
  9. Blood donation: blood donations for 3 months before this study
  10. Drug, alcohol, caffeine, tobacco: history of drug, alcohol [>1 drink/day for females and >2 drinks/day for men, defined according to the USDA Dietary Guidelines 2020-2025] or caffeine (>5 cups coffee/tea/day) abuse
  11. SARS-CoV-2 test: positive Covid-19 rapid test at Day -1
  12. Cotinine: positive cotinine test at screening
  13. Drug test: positive result at the urine drug screening test at screening or Day -1
  14. Alcohol test: positive alcohol saliva test at screening or Day -1
  15. Diet: abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians and vegans
  16. Pregnancy (women only): positive or missing pregnancy test at screening or Day -1; child-bearing potential, pregnant or lactating women.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Muut
  • Jako: Satunnaistettu
  • Inventiomalli: Peräkkäinen tehtävä
  • Naamiointi: Kolminkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: BAR502 single dose

Each subject will receive an oral single-dose of BAR 502 [Study Part A]
Lääke: BAR502 single dose

Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 150 mL of water, after an overnight fasting of at least 8 hours.

BAR 502 film-coated tablets are available at dose strengths of 3, 10 and 50mg. A maximum of 4 dose levels are pre-planned (3, 10, 30 and 60mg).
Placebo Comparator: Placebo single dose

Each subject will receive an oral single-dose of placebo [Study Part A]
Lääke: Placebo single dose

Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
Kokeellinen: BAR502 multiple doses

Each subject will receive a dose of BAR502 once a day for 14 days [Study Part B]
Lääke: BAR502 multiple doses

The 2 multiple ascending doses selected based on results of study part A will be administered to 2 study cohorts of 10 subjects each. The IMP will be orally administered once a day from Day 1 to Day 14, at 8:00±1 h, for a total of 14 doses.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Treatment-emergent adverse events
Aikaikkuna: PART A: Day-15/-2; Day-1 to Day4; Day 8; Day15 - PART B: Day-15/-2 to Day18; Day30

Safety will be evaluated through the assessment of adverse events
PART A: Day-15/-2; Day-1 to Day4; Day 8; Day15 - PART B: Day-15/-2 to Day18; Day30
Change in vital sign - BP
Aikaikkuna: PART A: Day-1 to Day4; Day 8; - PART B: Day-15/-2 to Day15; Day18

Tolerability will be evaluated throught the change in Blood preassure from baseline
PART A: Day-1 to Day4; Day 8; - PART B: Day-15/-2 to Day15; Day18
Change in vital sign - HR
Aikaikkuna: PART A: Day-1 to Day4; Day 8; - PART B: Day-15/-2 to Day15; Day18

Tolerability will be evaluated throught the change in Heart rate from baseline
PART A: Day-1 to Day4; Day 8; - PART B: Day-15/-2 to Day15; Day18

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Plasma BAR502 - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3, Day4

Plasma BAR502 concentration-time profile after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3, Day4
Urine BAR502 - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Urine BAR502 concentration-time profile after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Plasma BAR505 - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3, Day4

Plasma BAR505 concentration-time profiles after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3, Day4
Urine BAR505 - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Urine BAR505 concentration-time profiles after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Plasma BAR502 PK: Cmax - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3, Day4

Plasma BAR502 Cmax value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3, Day4
Plasma BAR502 PK: t_max - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3, Day4

Plasma BAR502 t_max value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3, Day4
Plasma BAR502 PK: AUC0-t - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3, Day4

Plasma BAR502 AUC0-t value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3, Day4
Urine BAR502 PK: Ae0-t - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Urine BAR502 Ae0-t value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Urine BAR502 PK: Fe0-t - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Urine BAR502 Fe0-t value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Urine BAR502 PK: Rmax - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Urine BAR502 Rmax value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Urine BAR502 PK: AUR_Clast - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Urine BAR502 AUR_Clast value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Urine BAR502 PK: REC% - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Urine BAR502 REC% value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Urine BAR502 PK: tu_max - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Urine BAR502 tu_max value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Urine BAR502 PK: Cl_r r - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Urine BAR502 Cl_r r value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Serum biomarker FGF19 - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Serum FGF19 baseline-corrected concentration-time profile after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Serum biomarker C4 - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Serum C4 baseline-corrected concentration-time profile and PD parameters after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Serum biomarker GLP-1 - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Serum GLP-1 baseline-corrected concentration-time profile after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Serum PD: Cb_max - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Serum Cb_max value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Serum PD: Cb_min - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Serum Cb_min value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Serum PD: tb_max - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Serum PD tb_max value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Serum PD: tb_min - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Serum tb_min value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Serum PD: AUbC_0-24 - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Serum AUbC_0-24 value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Serum PD: partial AUbC - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Serum partial AUbC value after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Serum total bile acids - Study Part A
Aikaikkuna: Day1 (pre- and post- dose), Day2, Day3

Serum total bile acids baseline-corrected concentration-time profiles after IMP single dose administration
Day1 (pre- and post- dose), Day2, Day3
Plasma BAR502 concentration - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day18

Plasma BAR502 concentration-time profile after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day18
Plasma BAR505 concentration - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day18

Plasma BAR505 concentration-time profile after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day18
Plasma BAR502 PK: Cmax - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day18

Plasma BAR502 Cmax value after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day18
Plasma BAR502 PK: t_max - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day18

Plasma BAR502 t_max value after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day18
Plasma BAR502 PK: AUC_0-24 - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day18

Plasma BAR502 AUC_0-24 value after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day18
Plasma BAR502 PK: AUC_0-t - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day18

Plasma BAR502 AUC_0-t value after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day18
Serum biomarker GLP-1 - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17

Serum GLP-1 baseline-corrected concentration-time profile after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17
Serum biomarker C4 - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17

Serum C4 baseline-corrected concentration-time profile after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17
Serum biomarker FGF19 - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17

Serum FGF19 baseline-corrected concentration-time profile after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17
Serum PD: Cb_max - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17

Serum Cb_max value after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17
Serum PD: Cb_min - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17

Serum Cb_min value after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17
Serum PD: tb_max - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17

Serum tb_max value after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17
Serum PD: tb_min - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17

Serum tb_min after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17
Serum PD: AUbC_0-24 - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17

Serum AUbC_0-24 value after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17
Serum PD: partial AUbC - Study Part B
Aikaikkuna: daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17

Serum partial AUbC value after IMP multiple dose
daily from Day1 to Day14 (pre- and post- dose); Day15 to Day17
Serum total bile acids - Study Part B
Aikaikkuna: Daily from Day1 to Day17

Serum total bile acids baseline-corrected concentration-time profiles after after IMP multiple dose
Daily from Day1 to Day17
Change in body weight
Aikaikkuna: PART A: Day1; Day 8 - PART B: Day1; Day18; Day30

Change in body weight from baseline after single and multiple IMP dose
PART A: Day1; Day 8 - PART B: Day1; Day18; Day30
Check for Physical abnormalities
Aikaikkuna: PART A: Day1; Day 8 - PART B: Day1; Day18; Day30

Change in Physical examination from baseline after single and multiple IMP dose
PART A: Day1; Day 8 - PART B: Day1; Day18; Day30
hepatic parameters: AST
Aikaikkuna: PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18

Change from baseline in AST value after single and multiple IMP dose
PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18
hepatic parameters: ALT
Aikaikkuna: PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18

Change from baseline in ALT value after single and multiple IMP dose
PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18
hepatic parameters: Total bilirubin
Aikaikkuna: PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18

Change from baseline in Total bilirubin value after single and multiple IMP dose
PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18
hepatic parameters: Direct bilirubin
Aikaikkuna: PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18

Change from baseline in Direct bilirubin value after single and multiple IMP dose
PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18
hepatic parameters: Indirect bilirubin
Aikaikkuna: PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18

Change from baseline in Indirect bilirubin value after single and multiple IMP dose
PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18
hepatic parameters: Total cholesterol
Aikaikkuna: PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18

Change from baseline in Total cholesterol value after single and multiple IMP dose
PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18
hepatic parameters: HDL cholesterol
Aikaikkuna: PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18

Change from baseline in HDL cholesterol value after single and multiple IMP dose
PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18
hepatic parameters: LDL cholesterol
Aikaikkuna: PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18

Change from baseline in LDL cholesterol value after single and multiple IMP dose
PART A: Day2; Day3; Day 8; - PART B: daily from Day2 to Day13; Day15; Day18
Change in Gallbladder contraction - Study Part B
Aikaikkuna: daily from Day2 to Day13; Day15

Change from baseline in Gallbladder contraction after IMP multiple dose
daily from Day2 to Day13; Day15
Change in Gallbladder volume - Study Part B
Aikaikkuna: daily from Day2 to Day13; Day15

Change from baseline in Gallbladder volume after IMP multiple dose
daily from Day2 to Day13; Day15
Change in ECG trace: PR
Aikaikkuna: PART A: daily from Day1 to Day 4 - PART B: daily from Day to Day15

Change from baseline in ECG trace PR interval value after single and multiple IMP dose
PART A: daily from Day1 to Day 4 - PART B: daily from Day to Day15
Change in ECG trace: QRS
Aikaikkuna: PART A: daily from Day1 to Day 4 - PART B: daily from Day to Day15

Change from baseline in ECG trace QRS interval value after single and multiple IMP dose
PART A: daily from Day1 to Day 4 - PART B: daily from Day to Day15
Change in ECG trace: QT
Aikaikkuna: PART A: daily from Day1 to Day 4 - PART B: daily from Day to Day15

Change from baseline in ECG trace QT interval value after single and multiple IMP dose
PART A: daily from Day1 to Day 4 - PART B: daily from Day to Day15
Change in ECG trace: QTcB
Aikaikkuna: PART A: daily from Day1 to Day 4 - PART B: daily from Day to Day15

Change from baseline in ECG trace QT interval corrected with Bazett's formula after single and multiple IMP dose
PART A: daily from Day1 to Day 4 - PART B: daily from Day to Day15
Change in ECG trace: QTcF
Aikaikkuna: PART A: daily from Day1 to Day 4 - PART B: daily from Day to Day15

Change from baseline in ECG trace QT interval corrected with Fridericia's formula after single and multiple IMP dose
PART A: daily from Day1 to Day 4 - PART B: daily from Day to Day15
Change in ECG: Heart rate
Aikaikkuna: PART A: daily from Day1 to Day 4 - PART B: daily from Day to Day15

Change from baseline in ECG Heart rate after single and multiple IMP dose
PART A: daily from Day1 to Day 4 - PART B: daily from Day to Day15

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

BAR Pharmaceuticals s.r.l.

Tutkijat

  • Päätutkija: Milko Radicioni, MD, CROSS Research S.A., Phase I Unit

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Keskiviikko 4. joulukuuta 2024

Ensisijainen valmistuminen (Todellinen)

Keskiviikko 3. kesäkuuta 2026

Opintojen valmistuminen (Todellinen)

Keskiviikko 3. kesäkuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 23. elokuuta 2024

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 22. marraskuuta 2024

Ensimmäinen Lähetetty (Todellinen)

Tiistai 26. marraskuuta 2024

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 21. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 16. syyskuuta 2026

Viimeksi vahvistettu

Tiistai 1. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • BAR-502-001

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa